N-(2-(4-((3-(2-allylphenoxy)-2-hydroxypropyl)amino)-4-methylcyclohexyl)propan-2-yl)-2-bromoacetamide

Catalog No. :
ACLIVX532
CAS No. :
76298-89-0
Molecular Formula :
C24H37BrN2O3
Molecular Weight :
480.2

IUPAC Name:N-(2-(4-((3-(2-allylphenoxy)-2-hydroxypropyl)amino)-4-methylcyclohexyl)propan-2-yl)-2-bromoacetamide

N-(2-(4-((3-(2-allylphenoxy)-2-hydroxypropyl)amino)-4-methylcyclohexyl)propan-2-yl)-2-bromoacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(2-(4-((3-(2-allylphenoxy)-2-hydroxypropyl)amino)-4-methylcyclohexyl)propan-2-yl)-2-bromoacetamide
IUPAC NameN-(2-(4-((3-(2-allylphenoxy)-2-hydroxypropyl)amino)-4-methylcyclohexyl)propan-2-yl)-2-bromoacetamide
Molecular FormulaC24H37BrN2O3
Molecular Weight480.2
SMILESO=C(CBr)NC(C)(C1CCC(C)(CC1)NCC(COC2=C(CC=C)C=CC=C2)O)C
InChI KeyUAXZWLFRPNDCMX-UHFFFAOYSA-N
Synonym1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol;2-bromo-N-[2-[4-[[2-hydroxy-3-(2-prop-2-enylphenoxy)propyl]amino]-4-methylcyclohexyl]propan-2-yl]acetamide;BrAAM;Acetamide, 2-bromo-N-[1-[4-[[2-hydroxy-3-[2-(2-propen-1-yl)phenoxy]propyl]amino]-4-methylcyclohexyl]-1-methylethyl]-
CAS No.76298-89-0

Synthetic Route by SureRoute

1. ACLIVX532 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLIVX532 route product structure diagram
    ACLIVX53276298-89-0
Inquiry

2. ACLIVX532 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLIVX532 route product structure diagram
    ACLIVX53276298-89-0
Inquiry

Comments (0)